Navigation Links
CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
Date:9/6/2011

KING OF PRUSSIA, Pa., Sept. 6, 2011 /PRNewswire/ -- To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards.  Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.

From the management of primary immunodeficiency to the control of autoimmune and inflammatory conditions, Ig therapy has a wide range of indications. The Interlaken Leadership Awards program was created to help identify new clinical applications for polyvalent immunoglobulins for potential further clinical investigation, with the ultimate goal of having a positive impact on the quality of life for people who are diagnosed with a wide range of neurological conditions, for example, multifocal motor neuropathy, myasthenia gravis, and chronic pain.

"The number of potential clinical applications for immunoglobulin therapy continues to expand and recent research has identified several novel and promising uses that may be able to help people with debilitating and degenerative neurological conditions," said Jeffrey Baggish, M.D., Director of Medical Affairs, Immunology & Pulmonary at CSL Behring. "The Interlaken Leadership Awards further underpins CSL Behring's position at the forefront of immunoglobulin research by supporting investigators who are devoted to improving patient outcomes by advancing the evolving science behind Ig therapy."

Proposal Submission Process

Any individual actively engaged in clinical or basic research in a field of study consistent with the goals of the Interlaken Leadership Awards program is eligible.  

For more information, please visit: www.InterlakenLeadershipAwards.com.  

About the International Immunoglobulin Symposium in Interlaken

For more than three decades, CSL Behring has sponsored a high-level scientific symposium in Interlaken, Switzerland. First held in 1981, and most recently in 2009, the International Immunoglobulin Symposium focuses exclusively on scientific and clinical research in the field of polyvalent immunoglobulins.

Research presented at the Interlaken symposium is consistently at the forefront of immunoglobulin research. Since its inception, the International Immunoglobulin Symposium has won the respect and support of top international scientists and clinicians from many different fields of research. For more information, please visit: http://www.interlakenleadershipawards.com/symposium.aspx.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Contact:
Greg Healy, Senior Manager, Communications & Public Relations
Commercial Operations
CSL Behring
610-878-4841
Greg.Healy@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
5. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
6. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
10. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
11. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
Breaking Medicine News(10 mins):